Treatment Sequencing Decisions in ALK+ NSCLC
This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.
EP: 1.Sarah’s Journey With ALK+ Metastatic NSCLC
EP: 2.The Role of Molecular Testing in Treatment Decisions for NSCLC
EP: 3.The Benefits of Lorlatinib for ALK+ NSCLC: CROWN Update
EP: 4.Assessing Treatment Options for ALK+ NSCLC
Now Viewing
EP: 5.Treatment Sequencing Decisions in ALK+ NSCLC
EP: 6.Overview of Emerging ALK+ NSCLC Treatments
EP: 7.Eleanor’s Journey With KRAS+ Metastatic NSCLC
EP: 8.Overview of the Efficacy Data of Adagrasib in the Treatment of KRAS+ NSCLC
EP: 9.KRAS G12 Inhibitor Treatment Options
EP: 10.Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
EP: 11.KRAS+ NSCLC: Treatment Management Strategies
EP: 12.Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment
Video content above is prompted by the following:
- If this patient were to experience disease progression on lorlatinib, what would be your next therapeutic approach and why?
- What considerations would guide your decision-making process?
- If this patient had started on a different ALK inhibitor, when/why might you consider a switch to lorlatinib?
Recent Videos
